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Cardiac noninvasive imagingCardiac tumors are rare. Cardiac tumors comprise primary and
secondary metastatic tumors. The frequency of cardiac tumors is
low with an estimated cumulative prevalence of approximately
0.002% by autopsy or 0.15% by echocardiographic evaluations
[1,2]. The majority of primary cardiac tumors are benign
(approximately 75% of primary tumors), and of those, myxoma
is the commonest (more than 50% of primary benign cardiac
tumors), followed by ﬁbroelastoma, ﬁbromas, rhabdomyoma,
hemangioma, and lipomas [3]. Primary malignant cardiac tumors
are also rare and can be broadly divided into sarcomas, malignant
lymphomas, and pericardial mesothelioma [4]. Of those, cardiac
sarcomas are predominant. Angiosarcoma is the commonest
primary malignant tumor in adulthood, while rhabdomyosarcoma
is more frequently observed in children [4,5]. Metastatic cardiac
tumors are more frequent than primary tumors with a ratio of
approximately 40 times [6]. The incidence reportedly ranges from
2.3% to 18.3% [7]. In autopsy reports, patients with known
malignant neoplasmas have cardiac metastatic involvement in
10–12% of cases [8]. The commonest metastatic cardiac tumor is
bronchogenic carcinoma, followed by malignant lymphomas,
malignant melanoma, leukemia, and carcinomas from the breast,
esophagus, and kidney. The commonest site of involvement is the
pericardium with or without invasion of the myocardium, and
progressive pericardial effusion is observed.
In the primary benign tumors, myxoma is thought to arise from
pluripotent mesenchymal cells associated with embryonal resi-
dues in the subendocardium [9,10]. The conﬁguration is polypoid
and pedunculated with a lobulated surface. Some of them show
malignant transformation. The majority (approximately 75%) of
myxomas develop in the left atrium. Others arise from the right
atrium. Most arise from a narrow attachment point at the fossa
ovalis of the interatrial septum. Left atrial myxomas hemodynam-
ically mimic mitral stenosis, leading to dyspnea or orthopnea.
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in 30–40% of patients and is frequently to the cerebral circulation
[13]. Papillary ﬁbroelastoma is the second commonest benign
cardiac tumor [11]. This tumor is histologically composed of a
ﬁne meshwork collagen and elastic ﬁber covered by endothelium.
The atrial surfaces of the mitral valve and aortic valve are the
commonest sites. Fibroma is well-circumscribed aggregates of
collagen and ﬁbroblast and arises in the intramyocardium
[11]. This tumor is frequently observed in infants and children.
Rhabdomyoma is also observed in children (approximately 90%
of primary cardiac tumors in children) [11]. Lipoma is a neoplasm
composed of adipose tissue [11]. Hemangioma is a rare tumor
which is discovered accidentally in the myocardium by autopsy,
and does not cause clinical problems [11].
In primary malignant cardiac tumors, sarcomas are predomi-
nant [2,14]. In particular, angiosarcoma is the commonest tumor.
This tumor is composed of irregularly shaped vascular channels
related to anaplastic epithelial cells with sizable areas of necrosis
and hemorrhage. This tumor is frequently observed in the fourth
decade male, and raises from the right atrium. This tumor typically
invades the right atrial chamber with extensive inﬁltration into
adjacent structures which correspond to the pericardium, vena
cavae, tricuspid valve, right coronary artery, and right ventricle.
Metastasis is often found in the lungs, liver, bones, and brain,
resulting in poor prognosis. Sarcomas with myoﬁbroblastic
differentiation are a diverse group of primary malignant cardiac
tumors which contain heterogeneous elements [14]. These sarco-
mas are classiﬁed into three malignant tumors as follows:
undifferentiated sarcomas, liposarcoma, and leiomyosarcoma
[14]. These tumors are often observed in the left atrial posterior
wall and typically exhibit slow inﬁltration into adjacent structures.
Rhabdomyosarcoma comprising embryonal cells is one of the
common primary pediatric cardiac tumors [14]. Primary cardiac
lymphoma is much more infrequent than secondary involvement.
This is exceedingly rare, representing approximately 1% of primary
cardiac tumors [15]. The majority occurs in immunocompromised
patients, and is of B-cell origin. The right atrium is the commonest
site of origin with frequent involvement of more than 1 chamber
and pericardial invasion.
In metastatic cardiac tumors, the incidence of metastatic
secondary cardiac tumors is approximately 40 times more
frequent than that of primary ones, but most of them remain
clinically silent [7]. They generally appear late after the onset of the
primary disease and isolated cardiac involvement is rarely
observed without dissemination to the other organs. Since the
pericardium is more often involved than the myocardium, reserved.
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commonly observed symptoms owing to accumulation of malig-
nant pericardial effusion.
Clinical manifestations of cardiac tumors are diverse and
nonspeciﬁc. There are no typical symptoms which depend on
tumor size and locations. Most tumors remain clinically silent,
while some of them present with symptoms, for example dyspnea,
orthopnea, chest pain, or edema on lower legs, relating with
intracardiac obstruction, arrhythmias, or systematic obstruction.
The primary benign cardiac tumors are usually resected with
minimal morbidity and most patients have a good clinical course.
However, some benign tumors need surgical operations dependent
on the risk of complications, tumor size, or locations. Some
malignant tumors may be treated with surgical resection if they
are discovered in the early phase, but generally their prognosis
is not so good even if chemotherapies are administered [11,16,17].
Actually, integrated chemotherapies are partially effective for
primary and secondary malignant cardiac tumors.
In general, trans-thoracic echocardiography (TTE) is a ﬁrst-line,
convenient, and useful modality to detect cardiac tumors.
However, TTE cannot fully evaluate an invading cardiac mass
due to a limitation of ﬁeld-of-view [18]. Trans-esophageal
echocardiography (TEE) provides more detailed information about
small masses and masses particularly those inﬁltrated into the
atrium or cardiac valves [19]. However, TEE is a more uncomfort-
able test for patients than TTE. In addition, both TTE and TEE cannot
provide precise tissue characterizations and conﬁdential differ-
entiations between thrombus and tumors [20]. Electrocardio-
graphically gated multi-detector computed tomography (MDCT)
scanners have recently merged acquisition speed and high special
resolution with volumetric scanning to provide excellent anatomic
details. MDCT provides complemental assessments of cardiac
muscle with coronary artery conﬁguration [21,22]. However,
MDCT cannot differentiate the detailed soft-tissue characterization
and offers a relatively high radiation exposure. Cardiac magnetic
resonance (CMR) imaging overcomes these ﬂaws of the above-
mentioned modalities, allowing integrated and comprehensive
assessments of the cardiac muscle, pericardium, and adjacent
organs, if patients do not have implanted ferromagnetic devices or
are not claustrophobic [22]. This modality has several advantages
including an unrestricted ﬁeld-of-view and superior soft-tissue
contrast. This modality can be used to localize and characterize
cardiac masses with the use of the following techniques: CMR
pulse sequences, black-blood techniques, bright-blood techniques,
and ﬁrst-pass perfusion and delayed enhancement imaging using
gadolinium contrast media.
In a case report by Pedrotti et al. [23], they present a rare
and unique case indicating metastatic melanoma, with a large
amount of effusion, in both the pericardium and myocardium. The
tumor origin was conﬁrmed as metastasis of melanoma by
echocardiography, cardiac CT, and CMR imaging, but the patho-
logical malignancy by pericardiocentesis was not evident. In
particular, CMR imaging provides great clues for the ﬁnal diagnosis
for identifying the origin (primary cardiac tumor or secondary
metastatic melanoma). Since melanoma signal characteristics are
dependent on the content of melanin, natural paramagnetic
substance causes T1-shortening. Then, melanoma indicates a
high signal on T1-images and low signal on T2-images. These
characteristics may help diagnose origins of metastatic tumors.
The ﬁnal diagnosis was deﬁned as metastasis of subcutaneous
melanoma operated 10 years previously by biopsy specimens.
They conclude that the comprehensive assessments using cardiac
noninvasive imaging modalities are crucial to enable the
diagnostic work-up in such a complex case.The diagnosis of cardiac tumors is difﬁcult. However, as
mentioned by Pedrotti et al., multi-disciplinary imaging approach
plays a key role in the diagnostic work-up and management of
complex cases with cardiac tumors.
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